En español
NIDA

Menu

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT)

This study will investigate the safety and efficacy of a combination pharmacotherapy – extended-release depot naltrexone plus extended-release bupropion for the treatment of methamphetamine dependence.  The double-blind, placebo-controlled study includes random assignment of methamphetamine-dependent participants to one of two conditions: active medication or placebo for 8 weeks of pharmacotherapy provided with weekly psychosocial treatment.

CTN Protocol ID: 
CTN-0054
Enrollment Status: 
Enrolling
Principal Investigator(s)
Walter Ling, M.D.
Director
Integrated Substance Abuse Programs
University of California, Los Angeles
11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025
lwalter@ucla.edu

Get this Publication

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.